Combination therapy facilitates optimal stem cell collection
Motixafortide plus standard stem cell therapy helped to “rapidly” mobilise stem cells in multiple myeloma, a Phase III trial has shown.
List view / Grid view
Motixafortide plus standard stem cell therapy helped to “rapidly” mobilise stem cells in multiple myeloma, a Phase III trial has shown.
The combination of motixafortide, KEYTRUDA® and chemotherapy met all trial endpoints, including increasing overall and progression free survival.